SIS17

Pricing Availability   Qty
说明: Selective HDAC11 inhibitor
化学名: N'-Hexadecylthiophene-2-carbohydrazide
纯度: ≥95% (HPLC)
说明书
引用文献
评论
文献 (3)

生物活性 for SIS17

SIS17 is a selective HDAC11 inhibitor (IC50 = 0.83 μM). Inhibits demyristoylation of serine hydroxymethyl transferase 2 with no detectable activity at other HDAC subtypes. Combination with Oxaliplatin (Cat. No. 2623) increases cytotoxicity to K562 cells; improves survival of Oxaliplatin-treated 769P cells. Cell permeable.

技术数据 for SIS17

分子量 366.61
公式 C21H38N2OS
储存 Store at -20°C
纯度 ≥95% (HPLC)
CAS Number 2374313-54-7
PubChem ID 139035087
InChI Key HSHXDCVZWHOWCS-UHFFFAOYSA-N
Smiles O=C(NNCCCCCCCCCCCCCCCC)C=1SC=CC1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for SIS17

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 3.67 10

制备储备液 for SIS17

以下数据基于产品分子量 366.61。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
0.1 mM 27.28 mL 136.38 mL 272.77 mL
0.5 mM 5.46 mL 27.28 mL 54.55 mL
1 mM 2.73 mL 13.64 mL 27.28 mL
5 mM 0.55 mL 2.73 mL 5.46 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

参考文献 for SIS17

参考文献是支持产品生物活性的出版物。

Son et al (2019) Activity-guided design of HDAC11-specific inhibitors. ACS Chem.Biol. 14 1393 PMID: 31264832

Li et al (2022) A pan-cancer analysis identifies HDAC11 as an immunological and prognostic biomarker. FASEB J. 36 e22326 PMID: 35657209


If you know of a relevant reference for SIS17, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 Class IV HDAC Inhibitors

关键词: SIS17, SIS17 supplier, SIS17, HDAC, HDAC11, inhibitors, inhibit, inhibits, selective, cytotoxicity, Class, IV, HDACs, 7969, Tocris Bioscience

篇 SIS17 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 SIS17 的引用文献。 您是否知道使用了 Tocris SIS17 的优秀论文? 请告知我们.

SIS17 的评论

目前没有该产品的评论。 Be the first to review SIS17 and earn rewards!

Have you used SIS17?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Cell Cycle & DNA Damage Repair Poster

Cell Cycle & DNA Damage Repair Poster

In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.